Thiotepa Riemser 欧盟 - 罗马尼亚文 - EMA (European Medicines Agency)

thiotepa riemser

esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - agenți antineoplazici - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Cellcept comprimate filmate 500 mg 摩尔多瓦 - 罗马尼亚文 - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

cellcept comprimate filmate 500 mg

roche registration ltd - micofenolat mofetil - comprimate filmate - 500 mg

Myclausen 欧盟 - 罗马尼亚文 - EMA (European Medicines Agency)

myclausen

passauer pharma gmbh - micofenolat de mofetil - respingerea grefei - imunosupresoare - myclausen este indicat în asociere cu ciclosporină și corticosteroizi pentru profilaxia rejetului de transplant acut la pacienții care primesc transplanturi allogeneice renale, cardiace sau hepatice.

Cabometyx 欧盟 - 罗马尼亚文 - EMA (European Medicines Agency)

cabometyx

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - agenți antineoplazici - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Myfortic 180 mg comprimate gastrorezistente 摩尔多瓦 - 罗马尼亚文 - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

myfortic 180 mg comprimate gastrorezistente

novartis pharma ag - acid mycophenolicum - comprimate gastrorezistente - 180 mg

Adakveo 欧盟 - 罗马尼亚文 - EMA (European Medicines Agency)

adakveo

novartis europharm limited - crizanlizumab - anemie, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Klacid I.V. 500 mg pulbere pentru soluţie perfuzabilă 摩尔多瓦 - 罗马尼亚文 - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

klacid i.v. 500 mg pulbere pentru soluţie perfuzabilă

abbott laboratories gmbh - clarithromycinum - pulbere pentru soluţie perfuzabilă - 500 mg

Cellcept capsule 250 mg 摩尔多瓦 - 罗马尼亚文 - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

cellcept capsule 250 mg

f.hoffmann-la roche ltd - capsule - 250 mg

Cellcept 500 mg comprimate filmate 摩尔多瓦 - 罗马尼亚文 - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

cellcept 500 mg comprimate filmate

f.hoffmann-la roche, ltd. - micofenolat mofetil - comprimate filmate - 500 mg

Klacid 250 mg/5 ml granule pentru suspensie orală 摩尔多瓦 - 罗马尼亚文 - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

klacid 250 mg/5 ml granule pentru suspensie orală

abbott laboratories gmbh - clarithromycinum - granule pentru suspensie orală - 250 mg/5 ml